LEADER 02366oam  2200733   450 
001 9910716970303321
005 20211103142540.0
024 8 $a70-300 O
035   $a(CKB)5470000002526491
035   $a(OCoLC)609101323$z(OCoLC)608084585$z(OCoLC)1011782402$z(OCoLC)1022006588$z(OCoLC)1069498955
035   $a(EXLCZ)995470000002526491
100   $a20100423g19809999  ua             0
101 0 $aeng
135   $aurbn||||||abp
135   $aurbn||||||ada
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug regulation reform--oversight $ehearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session ..
210  1$aWashington :$cU.S. G.P.O.,$d1980-
215   $a1 online resource
300   $aAccess ID (govinfo): CHRG-96hhrg70300Ov2.
300   $a"Serial no. 96-170."
300   $a"Serial no. 96-216."
327   $av. 1. New drug approval process -- v. 2. Orphan drugs.
517   $aDrug regulation reform--oversight 
606   $aPharmaceutical policy$zUnited States
606   $aDrugs$zUnited States$xTesting
606   $aPharmaceutical industry$zUnited States
606   $aDrug Industry
606   $aPharmaceutical Preparations$xstandards
606   $aResearch$xstandards
606   $aDrugs$xTesting$2fast
606   $aPharmaceutical industry$2fast
606   $aPharmaceutical policy$2fast
607   $aUnited States
607   $aUnited States$2fast
608   $aLegislative hearings.$2lcgft
615  0$aPharmaceutical policy
615  0$aDrugs$xTesting.
615  0$aPharmaceutical industry
615  2$aDrug Industry.
615  2$aPharmaceutical Preparations$xstandards.
615  2$aResearch$xstandards.
615  7$aDrugs$xTesting.
615  7$aPharmaceutical industry.
615  7$aPharmaceutical policy.
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCQ
801  2$bOCLCF
801  2$bOCLCO
801  2$bOCLCA
801  2$bOCLCQ
801  2$bNJR
801  2$bOCLCQ
801  2$bOCLCA
801  2$bUWO
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910716970303321
996   $aDrug regulation reform--oversight$93536321
997   $aUNINA